Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 250 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Polymorphism Clear all

Conditions: Blood Coagulation Disorders
Interventions: Warfarin Dosing; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Coronary Artery Disease
Interventions: Clopidogrel; Drug
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Infertility
Interventions: Not listed
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 50 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2026
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Rituximab, Tafasitamab; Procedure · Biological
Lead sponsor: Timothy Voorhees; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: New Brunswick, New Jersey • Hillsborough, North Carolina • Columbus, Ohio + 1 more

Conditions: Coronary Artery Disease
Interventions: Prasugrel, Ticagrelor; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 74 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Postoperative Nausea and Vomiting, Genetic Polymorphisms
Interventions: Ondansetron, Lorazepam, Aprepitant; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: San Francisco, California • Kansas City, Kansas • Lexington, Kentucky + 3 more

Conditions: Healthy, Pulmonary Fibrosis, Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Years
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute GVHD
Interventions: Tacrolimus; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Melanoma, Skin Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 4,082 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV-1 Seropositive, Inflammation, Cancer, Cardiomyopathy
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: HIV/AIDS
Interventions: Moxifloxacin, Placebo, Efavirenz; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Interaction
Interventions: Diclofenac, curcumin; Drug · Dietary Supplement
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions: Atropine, Exercise treadmill test; Drug · Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 6 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV
Interventions: Efavirenz; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Pain
Interventions: Valdecoxib, COX Inhibitor; Drug
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 7 Years to 35 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Heart Disease
Interventions: Blood Sample Collection; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: ALS
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: Not listed
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma, Inflammation
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 35 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neoplasms, Lymphomas
Interventions: Belinostat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 7
States / cities: Davis, California • Duarte, California • Los Angeles, California + 4 more

Conditions: Kidney Disease
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pelvic Organ Prolapse
Interventions: Not listed
Lead sponsor: Atlantic Health System; Other
Eligibility: Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Asthma
Interventions: salmeterol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts • Madison, Wisconsin

Conditions: Cancer, Breast Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care

Pilot Study on the Effect of High Clopidogrel Maintenance Dosing

Study of Gene Associations and Infertility

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:

Developing Individualized Strategies to Prevent Nausea and Vomiting

Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis

DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia

Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)

A Model for Genetic Susceptibility: Melanoma

Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac

Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics

Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain

Genetics of Congenital Heart Disease

Exposure to Neurotoxins as Risk Factors for ALS

Pathogenesis and Genetics of Environmental Asthma Ozone Study

Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction

Angiotensin-Converting Enzyme Gene Polymorphism and the Risk of Chronic Allograft Nephropathy

Do Patients With Early Post Operative Recurrence of Pelvic Organ Prolapse Have a Genetic Predisposition?

How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment

Role of Gene Variation in Effectiveness of Gleevec Treatment